drugset
Drugs / LP-168
last change Jun 2025 re-read 3 minutes ago

LP-168

Small molecule

Developed for
chronic lymphocytic leukemia/small lymphocytic lymphoma · mantle cell lymphoma · B-cell non-Hodgkin lymphoma · diffuse large B-cell lymphoma · follicular lymphoma · hairy cell leukemia · marginal zone lymphoma · Waldenstrom macroglobulinemia
Investigated by
Guangzhou Lupeng Pharmaceutical Company LTD. · Newave Pharmaceutical Inc · Zulfa Omer

Trials 6

today NCT06978088 · Ph 2 NCT06126861 · Ph 1 NCT05917964 · Ph 1 NCT05432713 · Ph 1 NCT04775745 · Ph 1 NCT04993690 · Ph 1
20222023202420252026202720282029
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 15 trials
Phase 1 NCT06126861 Dec 2023 → Feb 2024 — Guangzhou Lupeng Pharmaceutical Company LTD. Completed No outcome recorded
Phase 1 NCT05917964 Jun → Aug 2023 mantle cell lymphoma Guangzhou Lupeng Pharmaceutical Company LTD. Completed No outcome recorded
Phase 1 NCT05432713 May → Nov 2022 multiple sclerosis, neuromyelitis optica Guangzhou Lupeng Pharmaceutical Company LTD. Completed No outcome recorded
Phase 1 NCT04775745 Jul 2021 → Dec 2027 expected Waldenstrom macroglobulinemia, chronic lymphocytic leukemia/small lymphocytic lymphoma, diffuse large B-cell lymphoma, follicular lymphoma +3 Newave Pharmaceutical Inc Recruiting No outcome recorded
Phase 1 NCT04993690 Jul 2021 → Dec 2026 expected B-cell non-Hodgkin lymphoma Guangzhou Lupeng Pharmaceutical Company LTD. Recruiting No outcome recorded
Phase 21 trial
Phase 2 NCT06978088 Jun 2025 → Jun 2029 expected chronic lymphocytic leukemia/small lymphocytic lymphoma Zulfa Omer Recruiting No outcome recorded

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 6 sources stand behind the page.

FieldValueCited text
Known as LP-168 ClinicalTrials.gov intervention name — accepted as the source's own label NCT06978088 ↗
5

NCT05432713 ↗

NCT04775745 ↗

NCT06126861 ↗

NCT04993690 ↗

NCT05917964 ↗
Action Inhibit “LP-168 is a small molecule inhibitor.” NCT04775745 ↗
Modality Small molecule “LP-168 is a small molecule inhibitor.” NCT04775745 ↗
Route Oral “LP-168 administered once or twice daily as a single agent dosed orally” NCT04775745 ↗